Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Is momelotinib effective at improving anaemia and splenomegaly in MF?

Ruben Mesa • 2 Jun 2017
ASCO 2017
Myelofibrosis Momelotinib Ruxolitinib

Ruben Mesa, MD, FACP, from the Mayo Cancer Clinic Center, Rochester, MN, discusses the results from a Phase III trial comparing the efficacy of momelotinib versus ruxolitinib in participants with myelofibrosis (MF) who have not yet received treatment with a JAK inhibitor (NCT01969838). Two major unmet needs of patients with MF are improving anaemia and splenomegaly, as stated by Dr. Mesa, and momelotinib has been shown to be superior to ruxolitinib in improving these conditions, although the overall results are mixed. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

More from Ruben Mesa

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
2:08
Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET
Ruben Mesa • 9 Dec 2023
2:26
Assessing the impact of momelotinib on transfusion burden in MF: analysis of SIMPLIFY-1 & MOMENTUM
Ruben Mesa • 9 Dec 2023
2:20
Quantifying the anemia benefit of momelotinib in MF: analysis of data from SIMPLIFY-1 & SIMPLIFY-2
Ruben Mesa • 9 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals